Martin P, Dubois, et al.
Gut. 2014 Nov 26, doi: 10.1136/gutjnl-2014-308041 – Download the article
Publication
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
Par alcyon|2019-07-03T10:00:16+02:00novembre 26th, 2014|Publication, TG1050|Commentaires fermés sur TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
À propos de l'auteur : alcyon
Articles similaires
- TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity